VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Dreicer on Ongoing Trials in Prostate Cancer

Robert Dreicer, MD
Published: Tuesday, Jul 18, 2017



Robert Dreicer, MD, professor, University of Virginia Health System, discusses ongoing trials investigating emerging treatments for patients with prostate cancer.

There are ongoing trials suggesting that VT-464 may have some theoretical advantages for patients who have splice variants. It appears to be a safe agent with activity but the extent of the activity is still unknown.

EPI-506 is a different type of AR antagonist, which may also have activity in splice variants, however the phase II data is not yet mature.
 


Robert Dreicer, MD, professor, University of Virginia Health System, discusses ongoing trials investigating emerging treatments for patients with prostate cancer.

There are ongoing trials suggesting that VT-464 may have some theoretical advantages for patients who have splice variants. It appears to be a safe agent with activity but the extent of the activity is still unknown.

EPI-506 is a different type of AR antagonist, which may also have activity in splice variants, however the phase II data is not yet mature.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x